Comparative efficacy of pregabalin and benzodiazepines in treating the psychic and somatic symptoms of generalized anxiety disorder (Q43279625)

18 November 2017

Comparative efficacy of pregabalin and benzodiazepines in treating the psychic and somatic symptoms of generalized anxiety disorder (English)

1 reference

18 November 2017

R Bruce Lydiard

1

1 reference

18 November 2017

Karl Rickels

series ordinal

2

1 reference

18 November 2017

Barry Herman

series ordinal

3

1 reference

18 November 2017

Douglas E Feltner

series ordinal

4

1 reference

18 November 2017

9 September 2009

1 reference

The International Journal of Neuropsychopharmacology

18 November 2017

1 reference

18 November 2017

13

1 reference

18 November 2017

2

1 reference

18 November 2017

229-241

1 reference

Inhibition of K(+)-evoked glutamate release from rat neocortical and hippocampal slices by gabapentin

18 November 2017

1 reference

https://api.crossref.org/works/10.1017%2FS1461145709990460

7 January 2021

Pregabalin and gabapentin reduce release of substance P and CGRP from rat spinal tissues only after inflammation or activation of protein kinase C

1 reference

https://api.crossref.org/works/10.1017%2FS1461145709990460

7 January 2021

Dosing strategies for antidepressant clinical trials: a commentary

1 reference

https://api.crossref.org/works/10.1017%2FS1461145709990460

7 January 2021

Paroxetine treatment of generalized anxiety disorder: a double-blind, placebo-controlled study.

1 reference

https://api.crossref.org/works/10.1017%2FS1461145709990460

7 January 2021

Somatic symptoms in generalized anxiety disorder with and without comorbid psychiatric disorders.

1 reference

https://api.crossref.org/works/10.1017%2FS1461145709990460

7 January 2021

Long-term Treatment of Anxiety and Risk of Withdrawal

1 reference

https://api.crossref.org/works/10.1017%2FS1461145709990460

7 January 2021

Efficacy of extended-release venlafaxine in nondepressed outpatients with generalized anxiety disorder.

1 reference

https://api.crossref.org/works/10.1017%2FS1461145709990460

7 January 2021

Pregabalin for treatment of generalized anxiety disorder: a 4-week, multicenter, double-blind, placebo-controlled trial of pregabalin and alprazolam

1 reference

https://api.crossref.org/works/10.1017%2FS1461145709990460

7 January 2021

Antidepressants for the treatment of generalized anxiety disorder. A placebo-controlled comparison of imipramine, trazodone, and diazepam

1 reference

https://api.crossref.org/works/10.1017%2FS1461145709990460

7 January 2021

Fear and anxiety: divergent effects on human pain thresholds.

1 reference

https://api.crossref.org/works/10.1017%2FS1461145709990460

7 January 2021

REPLICATION OF FACTORS OF PSYCHOPATHOLOGY IN INTERVIEW, WARD BEHAVIOR AND SELF-REPORT RATINGS OF HOSPITALIZED DEPRESSIVES

1 reference

https://api.crossref.org/works/10.1017%2FS1461145709990460

7 January 2021

Paroxetine in the treatment of generalized anxiety disorder: results of a placebo-controlled, flexible-dosage trial

1 reference

https://api.crossref.org/works/10.1017%2FS1461145709990460

7 January 2021

Efficacy of pregabalin in the treatment of generalized anxiety disorder: double-blind, placebo-controlled comparison of BID versus TID dosing

1 reference

https://api.crossref.org/works/10.1017%2FS1461145709990460

7 January 2021

Efficacy and safety of pregabalin in the treatment of generalized anxiety disorder: a 6-week, multicenter, randomized, double-blind, placebo-controlled comparison of pregabalin and venlafaxine

1 reference

https://api.crossref.org/works/10.1017%2FS1461145709990460

7 January 2021

Pattern of symptom improvement following treatment with venlafaxine XR in patients with generalized anxiety disorder.

1 reference

https://api.crossref.org/works/10.1017%2FS1461145709990460

7 January 2021

Pooled analysis of venlafaxine XR efficacy on somatic and psychic symptoms of anxiety in patients with generalized anxiety disorder

1 reference

https://api.crossref.org/works/10.1017%2FS1461145709990460

7 January 2021

Gabapentin inhibits the substance P-facilitated K(+)-evoked release of [(3)H]glutamate from rat caudial trigeminal nucleus slices

1 reference

https://api.crossref.org/works/10.1017%2FS1461145709990460

7 January 2021

Past-year use of outpatient services for psychiatric problems in the National Comorbidity Survey.

1 reference

https://api.crossref.org/works/10.1017%2FS1461145709990460

7 January 2021

Prevalence, severity, and comorbidity of 12-month DSM-IV disorders in the National Comorbidity Survey Replication

1 reference

https://api.crossref.org/works/10.1017%2FS1461145709990460

7 January 2021

Venlafaxine ER as a treatment for generalized anxiety disorder in older adults: pooled analysis of five randomized placebo-controlled clinical trials

1 reference

https://api.crossref.org/works/10.1017%2FS1461145709990460

7 January 2021

Efficacy of pregabalin and venlafaxine-XR in generalized anxiety disorder: results of a double-blind, placebo-controlled 8-week trial

1 reference

https://api.crossref.org/works/10.1017%2FS1461145709990460

7 January 2021

Chronicity, relapse, and illness--course of panic disorder, social phobia, and generalized anxiety disorder: findings in men and women from 8 years of follow-up.

1 reference

https://api.crossref.org/works/10.1017%2FS1461145709990460

7 January 2021

Development of a Rating Scale for Primary Depressive Illness

1 reference

https://api.crossref.org/works/10.1017%2FS1461145709990460

7 January 2021

The assessment of anxiety states by rating

1 reference

https://api.crossref.org/works/10.1017%2FS1461145709990460

7 January 2021

The novel anticonvulsant drug, gabapentin (Neurontin), binds to the alpha2delta subunit of a calcium channel

1 reference

https://api.crossref.org/works/10.1017%2FS1461145709990460

7 January 2021

Potent and stereospecific anticonvulsant activity of 3-isobutyl GABA relates to in vitro binding at a novel site labeled by tritiated gabapentin.

1 reference

https://api.crossref.org/works/10.1017%2FS1461145709990460

7 January 2021

Analysis of the rate of improvement of specific psychic and somatic symptoms of general anxiety disorder during long-term treatment with venlafaxine ER.

1 reference

https://api.crossref.org/works/10.1017%2FS1461145709990460

7 January 2021

Inhibition of neuronal Ca(2+) influx by gabapentin and pregabalin in the human neocortex

1 reference

https://api.crossref.org/works/10.1017%2FS1461145709990460

7 January 2021

A randomized, double-blind, placebo-controlled, fixed-dose, multicenter study of pregabalin in patients with generalized anxiety disorder

1 reference

https://api.crossref.org/works/10.1017%2FS1461145709990460

7 January 2021

Analysis of individual symptoms in generalized anxiety--a pooled, multistudy, double-blind evaluation of buspirone

1 reference

https://api.crossref.org/works/10.1017%2FS1461145709990460

7 January 2021

10.1017/S1461145709990460

Identifiers

DOI

1 reference

18 November 2017

1 reference